GB201118201D0 - Novel peptides - Google Patents

Novel peptides

Info

Publication number
GB201118201D0
GB201118201D0 GBGB1118201.1A GB201118201A GB201118201D0 GB 201118201 D0 GB201118201 D0 GB 201118201D0 GB 201118201 A GB201118201 A GB 201118201A GB 201118201 D0 GB201118201 D0 GB 201118201D0
Authority
GB
United Kingdom
Prior art keywords
novel peptides
chaperonin
polypeptide
medicine
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1118201.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revolo Biotherapeutics Ltd
Original Assignee
Helperby Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helperby Therapeutics Ltd filed Critical Helperby Therapeutics Ltd
Priority to GBGB1118201.1A priority Critical patent/GB201118201D0/en
Publication of GB201118201D0 publication Critical patent/GB201118201D0/en
Priority to JP2014536330A priority patent/JP6199296B2/ja
Priority to EP12775541.1A priority patent/EP2768850B1/en
Priority to PCT/GB2012/052586 priority patent/WO2013057499A1/en
Priority to ES12775541T priority patent/ES2770438T3/es
Priority to CA2852381A priority patent/CA2852381C/en
Priority to US14/120,259 priority patent/US9320791B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
GBGB1118201.1A 2011-10-21 2011-10-21 Novel peptides Ceased GB201118201D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB1118201.1A GB201118201D0 (en) 2011-10-21 2011-10-21 Novel peptides
JP2014536330A JP6199296B2 (ja) 2011-10-21 2012-10-19 新規ペプチド
EP12775541.1A EP2768850B1 (en) 2011-10-21 2012-10-19 Novel peptides
PCT/GB2012/052586 WO2013057499A1 (en) 2011-10-21 2012-10-19 Novel peptides
ES12775541T ES2770438T3 (es) 2011-10-21 2012-10-19 Péptidos novedosos
CA2852381A CA2852381C (en) 2011-10-21 2012-10-19 Chaperonin 60.1 derived peptides for use in treatment of non-allergic inflammation
US14/120,259 US9320791B2 (en) 2011-10-21 2014-05-14 Peptides from chaperonin 60.1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1118201.1A GB201118201D0 (en) 2011-10-21 2011-10-21 Novel peptides

Publications (1)

Publication Number Publication Date
GB201118201D0 true GB201118201D0 (en) 2011-12-07

Family

ID=45373221

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1118201.1A Ceased GB201118201D0 (en) 2011-10-21 2011-10-21 Novel peptides

Country Status (7)

Country Link
US (1) US9320791B2 (https=)
EP (1) EP2768850B1 (https=)
JP (1) JP6199296B2 (https=)
CA (1) CA2852381C (https=)
ES (1) ES2770438T3 (https=)
GB (1) GB201118201D0 (https=)
WO (1) WO2013057499A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358957B2 (en) 2017-01-12 2025-07-15 Revolo Biotherapeutics Limited Method for the acute treatment of atopic dermatitis and allergic skin hypersensitivity
US12331088B2 (en) 2017-01-12 2025-06-17 Revolo Biotherapeutics Limited Method for the treatment of a relapsing-remitting condition
GB201700557D0 (en) 2017-01-12 2017-03-01 Peptinnovate Ltd Novel peptides
GB201700555D0 (en) 2017-01-12 2017-03-01 Peptinnovate Ltd Method for the treatment of a relapsing-remitting condition
CN111944060B (zh) * 2020-07-29 2022-02-25 中国农业大学 一种兼具抗菌、抗炎、解毒活性的多功能杂合肽及其应用
EP4525906A1 (en) * 2022-05-16 2025-03-26 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating food allergies
WO2024218571A1 (en) * 2023-04-18 2024-10-24 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating eosinophilic esophagitis
WO2025037259A1 (en) * 2023-08-15 2025-02-20 Revolo Biotherapeutics Limited Methods and compositions for preventing or treating severe asthma
WO2025255468A2 (en) 2024-06-06 2025-12-11 Miguel Guzman Subcutaneous formulation of a peptide derived from chaperonin 60.1
WO2026024894A2 (en) 2024-07-24 2026-01-29 De Alba Jorge Sublingual formulations of a peptide derived from chaperonin 60.1 and related methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887481B1 (en) * 1998-12-16 2005-05-03 Agency For Science, Technology And Research Bacterial-derived molecules and therapeutic and diagnostic uses therefor
GB0028122D0 (en) 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
EP1996235A1 (en) * 2006-02-21 2008-12-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides, pharmaceutical compositions and methods for the prevention and the therapeutic treatment of inflammatory disorders
GB0803369D0 (en) * 2008-02-25 2008-04-02 Helperby Therapeutics Ltd Biological materials and uses thereof
WO2010006059A1 (en) * 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof

Also Published As

Publication number Publication date
US20140341932A1 (en) 2014-11-20
JP6199296B2 (ja) 2017-09-20
EP2768850B1 (en) 2019-11-27
ES2770438T3 (es) 2020-07-01
EP2768850A1 (en) 2014-08-27
WO2013057499A1 (en) 2013-04-25
CA2852381A1 (en) 2013-04-25
US9320791B2 (en) 2016-04-26
JP2014532395A (ja) 2014-12-08
CA2852381C (en) 2020-12-29

Similar Documents

Publication Publication Date Title
GB201118201D0 (en) Novel peptides
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MY172578A (en) Oral dosing of glp-1 compounds
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX2015000338A (es) Novedosa cepa de lactobacillus crispatus.
IN2014DN08721A (https=)
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX362456B (es) Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
IN2014MN01642A (https=)
PH12015501983B1 (en) Peptides and compositions for treatment of joint damage
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
NZ708727A (en) Conjugate compounds
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX2014015423A (es) Analogos de peptido de exedina-4.
MX2013004061A (es) Analogos de ciclosporina.
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
UA108636C2 (xx) Пептид
WO2015031778A3 (en) Compositions and methods for the treatment or prevention of tuberculosis
SG10201900541QA (en) Derivatives of xanthone compounds
MX2013007995A (es) Peptidos derivados de lactoferrina humana y su uso.
MX2013004062A (es) Analogos de ciclosporina.
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: PEPTINNOVATE LIMITED

Free format text: FORMER OWNER: HELPERBY THERAPEUTICS LIMITED

AT Applications terminated before publication under section 16(1)